Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Plitidepsin (Aplidin)
Overview
Plitidepsin is a cyclic depsipeptide originally isolated from the Mediterranean tunicate Aplidium albicans and now produced synthetically. It targets the eukaryotic elongation factor 1A2 (eEF1A2), leading to oxidative stress, cell cycle arrest, and apoptosis in malignant cells.
Mechanism of Action
The compound has demonstrated activity against multiple myeloma and other hematologic malignancies in preclinical models. Its unique mechanism distinguishes it from conventional chemotherapeutic agents.
Research Summary & Key Findings
Phase III trials in relapsed/refractory multiple myeloma did not meet primary endpoints for progression-free survival compared to standard therapies. Plitidepsin received conditional approval in Australia in 2018 for multiple myeloma but has not achieved FDA approval. It has also been investigated for antiviral activity, including preliminary studies in COVID-19.
Clinical Status
Plitidepsin (Aplidin) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Plitidepsin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Plitidepsin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Plitidepsin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Oncology
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...
View detailsBortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...
View detailsLutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...
View detailsLeuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...
View detailsNo lawful pathway today
Plitidepsin (Aplidin) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.